Diagnostic Accuracy of 99m Tc-Sestamibi SPECT/CT for Characterization of Solid Renal Masses.

Autor:	Parihar AS; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri., Mhlanga J; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.; Siteman Cancer Centre, Washington University School of Medicine, St. Louis, Missouri; and., Ronstrom C; Siteman Cancer Centre, Washington University School of Medicine, St. Louis, Missouri; and.; Division of Urology, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri., Schmidt LR; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri., Figenshau RS; Siteman Cancer Centre, Washington University School of Medicine, St. Louis, Missouri; and.; Division of Urology, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri., Dehdashti F; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.; Siteman Cancer Centre, Washington University School of Medicine, St. Louis, Missouri; and., Wahl RL; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri; rwahl@wustl.edu.; Siteman Cancer Centre, Washington University School of Medicine, St. Louis, Missouri; and.
Jazyk:	angličtina
Zdroj:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2023 Jan; Vol. 64 (1), pp. 90-95. Date of Electronic Publication: 2022 Jun 30.
DOI:	10.2967/jnumed.122.264329
Abstrakt:	Our objective was to assess the diagnostic accuracy of 99m Tc-sestamibi SPECT/CT for characterizing solid renal masses. Methods: Imaging and clinical records of patients who underwent 99m Tc-sestamibi SPECT/CT for clinical work-up of their solid renal masses from September 2018 to October 2021 were retrospectively reviewed. Histopathology formed the reference standard, and the diagnoses were categorized as malignant/concerning (renal cell carcinomas [RCCs] other than chromophobe histology) and benign/nonconcerning (oncocytic tumors including chromophobe RCC, other benign diagnoses) to calculate the sensitivity and specificity of 99m Tc-sestamibi SPECT/CT and contrast-enhanced CT (ceCT). The clinical reads of the SPECT/CT images were used for visual classification of the lesions. Additionally, the SPECT images were manually segmented to obtain the maximum and mean counts of the lesion and adjacent renal cortex and maximum and mean lesion Hounsfield units. Results: 99m Tc-sestamibi SPECT/CT was performed on 42 patients with 62 renal masses. A histopathologic diagnosis was available for 27 patients (18 male, 9 female) with 36 solid renal masses. ceCT findings were available for 20 of these patients. The most commonly identified single histologic type was clear cell RCC (13/36; 36.1%). Oncocytic tumors were the most common group of nonconcerning lesions (15/36), with oncocytoma as the predominant histologic type ( n = 6). The sensitivity and specificity of SPECT/CT for diagnosing a nonconcerning lesion were 66.7% and 89.5%, respectively, compared with 10% and 75%, respectively, for ceCT. The lesion-to-kidney ratios for maximum and mean counts and maximum lesion Hounsfield units showed significant differences between the 2 groups ( P < 0.05). The lesion-to-kidney mean count ratio at a cutoff of 0.46 showed a sensitivity and specificity of 87.5% and 86.67%, respectively, for detecting nonconcerning lesions, which was significantly higher than that of ceCT. Conclusion: The current literature on the utility of 99m Tc-sestamibi SPECT/CT for characterization of solid renal masses is limited. We offer additional evidence of the incremental value of 99m Tc-sestamibi SPECT/CT over ceCT for differentiating malignant or aggressive renal tumors from benign or indolent ones, thereby potentially avoiding overtreatment and its associated complications. Quantitative assessment can further increase the diagnostic accuracy of SPECT/CT and may be used in conjunction with visual interpretation. (© 2023 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu